Cytosorbents Co. (NASDAQ:CTSO) Sees Significant Increase in Short Interest

Cytosorbents Co. (NASDAQ:CTSO) was the recipient of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 1,930,000 shares, an increase of 5.5% from the January 15th total of 1,830,000 shares. Based on an average daily volume of 257,900 shares, the days-to-cover ratio is presently 7.5 days.

Cytosorbents Trading Down 9.2 %

NASDAQ CTSO opened at $1.18 on Wednesday. Cytosorbents has a 12 month low of $0.70 and a 12 month high of $1.61. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06. The company has a market capitalization of $64.52 million, a PE ratio of -3.28 and a beta of 0.61. The stock has a 50-day simple moving average of $1.00 and a 200 day simple moving average of $1.04.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Millennium Management LLC acquired a new position in Cytosorbents in the fourth quarter valued at about $30,000. Northern Trust Corp grew its stake in Cytosorbents by 22.3% in the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock valued at $83,000 after acquiring an additional 16,701 shares during the period. Avenir Corp grew its stake in Cytosorbents by 4.0% in the fourth quarter. Avenir Corp now owns 3,093,946 shares of the medical research company’s stock valued at $2,815,000 after acquiring an additional 118,387 shares during the period. Raymond James Financial Inc. acquired a new position in Cytosorbents in the fourth quarter valued at about $99,000. Finally, Renaissance Technologies LLC grew its stake in Cytosorbents by 10.6% in the fourth quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock valued at $80,000 after acquiring an additional 8,400 shares during the period. 32.87% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. StockNews.com assumed coverage on Cytosorbents in a research report on Friday, February 14th. They issued a “hold” rating for the company. HC Wainwright restated a “neutral” rating and set a $1.00 target price on shares of Cytosorbents in a research report on Monday, November 11th. Finally, D. Boral Capital restated a “buy” rating and set a $10.00 target price on shares of Cytosorbents in a research report on Monday, January 13th. Two investment analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Cytosorbents currently has an average rating of “Moderate Buy” and an average price target of $4.67.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.